文献速递头颈与中枢神经肿瘤

纠正肿瘤相关自然杀伤细胞线粒体复合物I缺陷可增强胶质母细胞瘤免疫治疗

Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma.
PubMed 文献 · Cancer Discov · 2026-01-01

该研究探讨胶质母细胞瘤(GBM)中自然杀伤(NK)细胞线粒体复合物I缺陷的机制。研究发现患者NK细胞氧化磷酸化及复合物I活性受损,NDUFA9是代谢适应的关键介质,其缺失通过代谢重编程和表观遗传改变削弱NK细胞抗肿瘤功能。白藜芦醇激活或过表达NDUFA9可恢复复合物I活性并增强NK细胞抗GBM功能。

要点

  • 胶质瘤患者NK细胞存在氧化磷酸化和线粒体复合物I活性受损。
  • NDUFA9缺失通过代谢重编程和H3K27me3表观调控削弱NK细胞功能。
  • 白藜芦醇激活或过表达NDUFA9可增强NK细胞抗GBM功能。

核心结论

  • 线粒体复合物I活性对NK细胞代谢适应和抗肿瘤功能至关重要。
  • NDUFA9是GBM中NK细胞免疫治疗的可成药靶点。

研究设计与样本

  • 研究纳入胶质瘤患者NK细胞,进行多组学分析。
  • 采用Ndufa9敲除NK细胞模型评估线粒体功能和抗肿瘤效应。

主要发现

  • 胶质瘤患者NK细胞氧化磷酸化和线粒体复合物I活性受损。
  • 多组学分析确定NDUFA9为NK细胞代谢适应的关键介质。
  • NDUFA9+ NK细胞丰度与患者预后相关。
  • Ndufa9敲除损害NK细胞线粒体功能、抗肿瘤疗效和记忆样表型,并触发向谷氨酰胺依赖的代谢重编程。
  • Ndufa9缺陷NK细胞中α-酮戊二酸/琥珀酸比值降低,通过诱导关键免疫功能基因上的转录抑制性组蛋白标记H3K27me3介导广泛的表观遗传重编程。

关键数值与推荐

  • 白藜芦醇介导的NDUFA9激活或过表达通过恢复复合物I活性增强NK细胞抗GBM功能。

临床怎么用

  • 靶向NDUFA9恢复线粒体复合物I活性可能增强NK细胞免疫治疗GBM的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Despite successful immuno-oncology therapies in other cancers, they have largely failed in glioblastoma (GBM). In this study, natural killer (NK) cells from patients with glioma show impaired oxidative phosphorylation and mitochondrial complex I activity. Multiomics profiling identified complex I subunit NDUFA9 as a critical mediator of NK cell metabolic fitness. The abundance of NDUFA9+ NK cells informed patient outcomes. Ndufa9 knockout in NK cells compromised mitochondrial function, antitumor efficacy, and the memory-like phenotype of NK cells by triggering a metabolic reprogramming toward glutamine dependence. The decreased α-ketoglutarate/succinate ratio in Ndufa9-deficient NK cells mediated widespread epigenetic reprogramming by inducing the transcriptionally repressive histone mark H3K27me3 on key immune function genes. Resveratrol-mediated NDUFA9 activation or its overexpression enhanced NK cell anti-GBM function by restoring complex I activity. Together, these findings reveal the critical role of mitochondrial complex I activity in NK cells and highlight its potential as an actionable target to enhance NK cell-based immunotherapy for patients with GBM. SIGNIFICANCE: This study reveals that NDUFA9 deficiency in mitochondrial complex I compromises metabolic fitness and impairs the antitumor activity of NK cells in GBM. We identify the mitochondrial complex I subunit NDUFA9 as a key pharmacologically targetable node for NK cell-based immunotherapy in GBM, leveraging metabolic reprogramming to enhance antitumor efficacy. See related commentary by Tiberti et al., p. 1727.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Zhou N, Fei F, Tang L, et al. Correcting Mitochondrial Complex I Defect in Tumor-Associated Natural Killer Cells Potentiates Immunotherapy for Glioblastoma. Cancer Discov. 2026. PMID: 41944586. doi:10.1158/2159-8290.CD-25-0643

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。